Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC
Phase 3
- Conditions
- Esophageal Cancer Stage IIBEsophageal Cancer Stage III
- Interventions
- Combination Product: Paclitaxel, Cisplatin Plus 5-FU (TCF)Radiation: radiochemotherapy
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2018-01-09
- Target Recruit Count
- 420
- Registration Number
- NCT03366883
- Locations
- 🇨🇳
TianjinCIH, Tianjin, Tianjin, China
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
Phase 3
- Conditions
- Susceptibility, GeneticChemotherapy Effect
- Interventions
- Drug: DT groupDrug: ET groupDrug: NX group
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2017-12-02
- Target Recruit Count
- 300
- Registration Number
- NCT03359694
- Locations
- 🇨🇳
Jin Zhang, Tianjin, China
Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer
Not Applicable
Not yet recruiting
- Conditions
- Supraglottic Cancer
- Interventions
- Radiation: RadiotherapyProcedure: Selective neck dissection
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2017-12-12
- Target Recruit Count
- 158
- Registration Number
- NCT03358602
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hopital, Tianjin, Tianjin, China
XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2017-11-28
- Target Recruit Count
- 456
- Registration Number
- NCT03355612
Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2017-11-28
- Target Recruit Count
- 20
- Registration Number
- NCT03348098
- Locations
- 🇨🇳
TianJin Medical University Cancer Institute and Hospital, Tianjin, China
An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric
Phase 2
- Conditions
- Esophagus Cancer, Stage IIIEsophageal Gastric Cardia Type MetaplasiaEsophagus Cancer, Stage IV
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2017-09-18
- Target Recruit Count
- 30
- Registration Number
- NCT03285906
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer
Phase 1
- Conditions
- Pancreatic Cancer Stage IIIPancreatic Cancer Stage IV
- Interventions
- Other: GPBSC
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2017-08-02
- Target Recruit Count
- 30
- Registration Number
- NCT03236883
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2019-12-04
- Target Recruit Count
- 20
- Registration Number
- NCT03222440
- Locations
- 🇨🇳
Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer
Phase 2
- Conditions
- Colon Cancer Liver Metastasis
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2017-06-27
- Target Recruit Count
- 200
- Registration Number
- NCT03175016
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2017-05-30
- Target Recruit Count
- 20
- Registration Number
- NCT03167385
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath